BR0314965A - Derivados de 2-oxodiidropiridina n-substituìdos - Google Patents
Derivados de 2-oxodiidropiridina n-substituìdosInfo
- Publication number
- BR0314965A BR0314965A BR0314965-0A BR0314965A BR0314965A BR 0314965 A BR0314965 A BR 0314965A BR 0314965 A BR0314965 A BR 0314965A BR 0314965 A BR0314965 A BR 0314965A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkylamino
- hydroxy
- alkoxy
- halogen
- Prior art date
Links
- ZPOODPZCZLCUAN-UHFFFAOYSA-N 3,4-dihydro-1h-pyridin-2-one Chemical class O=C1CCC=CN1 ZPOODPZCZLCUAN-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"DERIVADOS DE 2-OXODIIDROPIRIDINA N-SUBSTITUìDOS". A presente invenção se refere a um composto de fórmula (I): (em que Ar^ 1^ e Ar^ 2^ são independentemente arila ou heteroarila, qualquer um dos quais sendo opcionalmente substituído por um substituinte selecionado do grupo que consiste de ciano, halogênio, nitro, alquila inferior, halo-alquila inferior, hidróxi-alquila inferior, ciclo-alquila inferior, ciclo(alquil-inferior)-alquila inferior, alquenila inferior, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, alquilssulfonilamino inferior, arilssulfonilamino inferior, hidróxi, alcóxi inferior, haloalcóxi inferior, arilóxi, heteroarilóxi, alquiltio inferior, carboxila, formila, alcanoíla inferior, alcóxicarbonila inferior, carbamoíla, alquilcarbamoíla inferior, di-alquilcarbamoíla inferior, alquilssulfonila inferior, arilssulfonila, arila e heteroarila; R^ 1^ e R^ 2^ são independentemente alquila inferior, ciclo-alquila inferior, ciclo(alquil-inferior)-alquila inferior ou alcóxi inferior, qualquer um dos quais sendo opcionalmente substituído por um substituinte selecionado do grupo que consiste de halogênio, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidróxi, alcóxi inferior, formila, alcóxicarbonila inferior, alquilcarbamoíla inferior e dialquilcarbamoíla inferior; R^ 3^ R^ 4^ e R^ 5^ são independentemente hidrogênio, ciano, halogênio, hidróxi, ou alquila inferior, alcóxi inferior ou alquiltio inferior, os últimos três grupos sendo opcionalmente substituídos por um substituinte selecionado do grupo que consiste de halogênio, alquilamino inferior, di-alquilamino inferior, alcanoilamino inferior, hidróxi, alcóxi inferior, formila, alcóxicarbonila inferior, alquilcarbamoíla inferior e di-alquilcarbamoíla inferior), ou um sal ou éster do mesmo, em que tais compostos são de utilidade como agentes antagonistas do receptor do neuropeptídeo Y e também de utilidade como agentes destinados ao tratamento de bulimia, obesidade ou diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002287015 | 2002-09-30 | ||
| JP2002353202 | 2002-12-05 | ||
| PCT/JP2003/012290 WO2004031175A2 (en) | 2002-09-30 | 2003-09-25 | N-substituted-2-oxodihydropyridine derivatives as npy antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314965A true BR0314965A (pt) | 2005-08-02 |
Family
ID=32072466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314965-0A BR0314965A (pt) | 2002-09-30 | 2003-09-25 | Derivados de 2-oxodiidropiridina n-substituìdos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6869966B2 (pt) |
| EP (1) | EP1546133B1 (pt) |
| KR (1) | KR20050059217A (pt) |
| CN (1) | CN100528864C (pt) |
| AR (1) | AR041374A1 (pt) |
| AT (1) | ATE461191T1 (pt) |
| AU (1) | AU2003273522B2 (pt) |
| BR (1) | BR0314965A (pt) |
| CA (2) | CA2497237C (pt) |
| DE (1) | DE60331751D1 (pt) |
| MX (1) | MXPA05003293A (pt) |
| NO (1) | NO20052106L (pt) |
| PE (1) | PE20050087A1 (pt) |
| PL (1) | PL376475A1 (pt) |
| RU (1) | RU2005113310A (pt) |
| TW (1) | TW200407138A (pt) |
| WO (1) | WO2004031175A2 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2518465A1 (en) * | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR20060041309A (ko) * | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| JP2007505121A (ja) * | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| WO2005030751A2 (en) * | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EA013427B1 (ru) * | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
| JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| AU2006290205B2 (en) * | 2005-09-14 | 2012-12-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| PL1931350T5 (pl) * | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| CA2622642C (en) * | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US20100029941A1 (en) * | 2006-03-28 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| WO2007115967A1 (en) * | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Crystalline isopropanol solvate of glucokinase activator |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| KR20230006043A (ko) * | 2014-04-09 | 2023-01-10 | 제넨테크, 인크. | 약제의 제조 방법 |
| CN112194634B (zh) * | 2018-11-30 | 2022-08-12 | 华南农业大学 | 一种n-二氟甲基咪唑硫(硒)脲衍生物的制备方法 |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| MX2023001840A (es) | 2020-08-18 | 2023-03-13 | Merck Sharp & Dohme Llc | Agonistas de bicicloheptano pirrolidina de los receptores de orexina. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH234887A (de) * | 1942-12-11 | 1944-10-31 | Ag J R Geigy | Verfahren zur Herstellung von N-Cyclohexyl-6-pyridon-3-carbonsäurediäthylamid. |
| CZ403592A3 (en) * | 1992-02-20 | 1993-12-15 | Hoechst Ag | Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use |
| AU757290B2 (en) | 1998-03-25 | 2003-02-13 | Bristol-Myers Squibb Company | Imidazolone anorectic agents: II. phenyl derivatives |
| US7064142B2 (en) * | 2000-02-22 | 2006-06-20 | Banyu Pharmaceutical, Co., Ltd. | Imidazonline compounds |
-
2003
- 2003-08-15 US US10/641,017 patent/US6869966B2/en not_active Expired - Fee Related
- 2003-09-17 TW TW092125570A patent/TW200407138A/zh unknown
- 2003-09-22 PE PE2003000968A patent/PE20050087A1/es not_active Application Discontinuation
- 2003-09-24 AR ARP030103473A patent/AR041374A1/es unknown
- 2003-09-25 WO PCT/JP2003/012290 patent/WO2004031175A2/en not_active Ceased
- 2003-09-25 MX MXPA05003293A patent/MXPA05003293A/es unknown
- 2003-09-25 BR BR0314965-0A patent/BR0314965A/pt not_active Application Discontinuation
- 2003-09-25 AU AU2003273522A patent/AU2003273522B2/en not_active Ceased
- 2003-09-25 EP EP03755682A patent/EP1546133B1/en not_active Expired - Lifetime
- 2003-09-25 CA CA2497237A patent/CA2497237C/en not_active Expired - Fee Related
- 2003-09-25 DE DE60331751T patent/DE60331751D1/de not_active Expired - Lifetime
- 2003-09-25 CN CNB038233398A patent/CN100528864C/zh not_active Expired - Fee Related
- 2003-09-25 KR KR1020057005511A patent/KR20050059217A/ko not_active Withdrawn
- 2003-09-25 RU RU2005113310/04A patent/RU2005113310A/ru not_active Application Discontinuation
- 2003-09-25 PL PL03376475A patent/PL376475A1/xx not_active Application Discontinuation
- 2003-09-25 CA CA2726754A patent/CA2726754C/en not_active Expired - Fee Related
- 2003-09-25 AT AT03755682T patent/ATE461191T1/de not_active IP Right Cessation
-
2004
- 2004-07-27 US US10/899,162 patent/US7138525B2/en not_active Expired - Fee Related
-
2005
- 2005-04-29 NO NO20052106A patent/NO20052106L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1546133A2 (en) | 2005-06-29 |
| MXPA05003293A (es) | 2005-10-18 |
| CA2726754C (en) | 2013-04-02 |
| US20050009879A1 (en) | 2005-01-13 |
| PL376475A1 (en) | 2005-12-27 |
| US7138525B2 (en) | 2006-11-21 |
| DE60331751D1 (de) | 2010-04-29 |
| US6869966B2 (en) | 2005-03-22 |
| AU2003273522B2 (en) | 2009-05-21 |
| CN100528864C (zh) | 2009-08-19 |
| PE20050087A1 (es) | 2005-02-22 |
| ATE461191T1 (de) | 2010-04-15 |
| WO2004031175A2 (en) | 2004-04-15 |
| AU2003273522A1 (en) | 2004-04-23 |
| CA2726754A1 (en) | 2004-04-15 |
| RU2005113310A (ru) | 2005-11-10 |
| KR20050059217A (ko) | 2005-06-17 |
| TW200407138A (en) | 2004-05-16 |
| WO2004031175A3 (en) | 2005-02-24 |
| NO20052106L (no) | 2005-04-29 |
| AR041374A1 (es) | 2005-05-11 |
| EP1546133B1 (en) | 2010-03-17 |
| US20040072874A1 (en) | 2004-04-15 |
| CA2497237C (en) | 2011-03-29 |
| CA2497237A1 (en) | 2004-04-15 |
| CN1684954A (zh) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052106L (no) | N-substituerte-2-oksodihydropyridinderivater. | |
| BR0013041A (pt) | Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método | |
| BR112023002080A2 (pt) | Sirna modificado com atividade fora do alvo reduzida | |
| NO20023218D0 (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| AR042450A1 (es) | Indazolilpirrolotriazinas modificadas c-6 | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| UY26089A1 (es) | Inhibidores de la sorbitol deshidrogenasa | |
| MA30709B1 (fr) | Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3. | |
| KR20110042374A (ko) | Ｍｉｆ 조정인자 | |
| ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| UA99822C2 (ru) | Производные изоксазолина, композиции для борьбы с бесхребетным вредителем, способ борьбы с бесхребетным вредителем и способ защиты животного от бесхребетного паразитарного вредителя | |
| BRPI0809770B8 (pt) | Composto e composição para controlar uma praga de invertebrados | |
| WO2009068531A3 (en) | Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes | |
| NO20075384L (no) | Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer. | |
| CR9710A (es) | Proceso para la preparacion de ciertos derivados de fenilpropargileter | |
| EA200802052A1 (ru) | 2-(пиридин-2-ил)-пиримидины в качестве фунгицидов | |
| NO20081206L (no) | Isoquinolines derivatives as IGF -1R inhibitors | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| EP1783116A4 (en) | 2-PHENYLPYRIDINE DERIVATIVE | |
| DE69019293D1 (de) | Naphthyloxazolidon-Derivate. | |
| Radwan et al. | New insight into the bioactivity of substituted benzimidazole derivatives: Repurposing from anti-HIV activity to cell migration inhibition targeting hnRNP M | |
| Johannes et al. | Discovery of 6-aryl-azabenzimidaoles that inhibit the TBK1/IKK-ε kinases | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR078683A1 (es) | Compuesto de pirona y su uso para el control de plagas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |